Lançamento de biofungicida inovador alavanca a expansão global da Cogny.
The launch of Metabolic Protection biofungicide marks the leveraging of the expansion of the Cogny ecosystem as the first Brazilian multinational bio-input company. The new product is the result of five years of research, and represents a new concept in the management of foliar diseases, mainly focused on soybean cultivation, due to its innovation as the first 100% metabolite-based biofungicide.
The launch represents a strategic milestone for Cogny, which brings together Brazilian biologicals companies including Simbiose, Bioma, Biojet and Biograss under a single business ecosystem. Agronegócio Global has previously highlighted the country’s strong biologicals growth, supported by grower adoption, regulatory developments and an increasingly sophisticated domestic industry.
For Cogny, however, the opportunity extends beyond Brazil.
From microorganisms to metabolites
Metabolic Protection is based on a different technological approach from conventional microbial biologicals. Rather than relying on the microorganism itself as the active component, the technology uses compounds produced by microorganisms and extracted through industrial processes.
“Through technological levels within our industry, we were able to develop a product in which compounds are extracted from a microorganism, and these compounds act directly in the control and management of foliar diseases, with a particular focus at this stage on soybeans,” said Derik Chamberlain, Executive Commercial Director at Bioma.
The distinction could become increasingly relevant as biologicals manufacturers seek products with greater consistency, formulation flexibility and compatibility with established crop protection programs.
Chamberlain said the company sees significant commercial potential for the technology as demand for biological fungicides continues to expand.
“The biological fungicide market in agriculture has been growing very positively, with growth rates exceeding 25% or 30%,” he said. “As an innovation and technology company, our expectations and our commitment to this product are very strong.”
The launch also reflects Cogny’s strategy of developing technologies internally, from discovery and research through formulation and commercialization.
“Our DNA is to invest in technology and innovation,” Chamberlain said. “We discover a technology, develop it, create a formulation and then transform our research into commercial products.”
A broader biologicals platform
Metabolic Protection is being introduced alongside an increasingly broad portfolio of biological technologies within Cogny.
Simbiose, which is approaching its 20th anniversary, specializes in biological control products based on microorganisms for nematodes and diseases. Bioma, which is approaching its 10th year, has developed technologies including Bioma Phos, a phosphorus-solubilizing product developed in partnership with Embrapa, as well as biological nitrogen-fixation technologies and inoculants.
The combination gives Cogny exposure across several segments of biological agriculture, including nutrient-use efficiency, inoculation, nematode management and disease control.
The group is also using field performance to reinforce the commercial positioning of its technologies. “We are very proud to be recognized for the second consecutive year as a champion case and to deliver record productivity in Brazil,” said Luiz Felipe Fiorese, Head of Marketing and Communications at Cogny. “We are very happy that we can share this achievement with our customer and our consultants.”
From Brazilian innovation to global markets
Cogny’s ambitions extend well beyond its domestic market. Fiorese said the group has accelerated its internationalization strategy over the past five years and currently has technologies produced in Brazil commercially present in more than 15 countries.
The portfolio has reached markets ranging from the United States and Canada to Zambia and Zimbabwe, illustrating the company’s strategy of exporting Brazilian biological technology to both developed and emerging agricultural markets.
“We are very proud to say that Brazilian technology is being exported to the world in more than 15 countries through our ecosystem,” Fiorese said.
The company is now advancing regulatory processes in Europe and the Asia-Pacific region and has established an objective of reaching 30 active export markets by 2030.
“We are currently in 15 countries, but the path has already been established to almost double that number,” Fiorese said.
That international strategy places Cogny within a broader trend of Brazilian biologicals companies seeking to transition from domestic specialists into global technology suppliers. Brazil’s large-scale agriculture, extensive use of biologicals and diverse production environments have created a testing ground for technologies that can potentially be adapted to other agricultural systems.
Cogny targets the next generation of biologicals
For Marcelo de Godoy Oliveira, CEO of Cogny, Metabolic Protection is part of a larger technological roadmap rather than an isolated product launch.
The group is investing in what he describes as a new generation of biological technologies, including edited microorganisms, purified molecules produced by microorganisms and hybrid products.
“My new purpose is to bring the new generations of edited microorganisms, pure molecules produced by microorganisms and hybrid products,” Oliveira said. “We want to provide these solutions to growers so they can incorporate them into their management programs, not only for fertility, but also for pest and disease control, while taking these opportunities to international markets.”
The ambition, Oliveira said, is to transform the group from a collection of Brazilian biologicals businesses into an integrated technology platform capable of competing internationally.
“A Brazilian company is now becoming a multinational — the first Brazilian multinational in biological inputs,” the CEO said.
The Metabolic Protection launch therefore represents more than the introduction of a new biofungicide. It signals Cogny’s attempt to move up the biologicals value chain — from microbial products toward metabolite-based technologies and next-generation biological molecules — while simultaneously building an international commercial footprint.
As Brazil’s biologicals market matures, the ability to deliver differentiated technologies, demonstrate field performance and navigate international regulatory systems will increasingly determine which domestic companies can translate local innovation into global scale. Cogny is betting that its next generation of metabolite-based and microbial technologies can provide that bridge.
Receba a Newsletter hoje mesmo!
